---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-027336"
form_type: "8-K"
ticker: "NAMS"
cik: "0001936258"
company_name: "NewAmsterdam Pharma Co N.V."
filed_at: "2025-02-26T23:59:59+00:00"
generated_at: "2026-05-26T03:58:47.055297+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# NewAmsterdam reports FY2024 net loss $241.6M, cash $834M; EMA submission on track for 2H25

## Summary
- Cash, cash equivalents and marketable securities totaled $834.2M at Dec 31, 2024, up from $340.5M.
- Revenue of $45.6M (FY2023: $14.1M) driven by a clinical milestone and cost reimbursement.
- Net loss widened to $241.6M from $176.9M; R&D spend fell to $151.4M while SG&A rose to $70.4M.
- Phase 3 BROADWAY met primary endpoint with 33% LDL-C reduction; TANDEM FDC achieved 49% reduction; BROOKLYN showed 36% reduction.
- EMA submission planned for 2H25 via partner Menarini; USPTO issued obicetrapib solid-form patent until July 2043.

## SEC filing metadata
- accession: 0000950170-25-027336
- form_type: 8-K
- ticker: NAMS
- cik: 0001936258
- company_name: NewAmsterdam Pharma Co N.V.
- filed_at: 2025-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/0000950170-25-027336-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1936258/000095017025027336/nams-20250226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-027336
- JSON: https://secwatch.observer/filing/0000950170-25-027336.json
- Plain text: https://secwatch.observer/filing/0000950170-25-027336.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.